Cyriac Roeding: The U.S. Risks Losing Biotech Leadership, and It's Not Because of Regulation

Cyriac Roeding argues that the United States risks losing its leadership in biotechnology due to a venture capital funding shift heavily favoring AI, leaving biotech companies underfunded during critical development phases. China's share of global pharmaceutical licensing dollars has surged from under 5% to two-thirds in five years, exploiting the U.S. funding gap, prompting calls for a U.S. sovereign wealth fund to support biotech development.

This Wire brief sits within Fusion42's coverage of Biotech.